Rakhee Vaidya to Vincristine
This is a "connection" page, showing publications Rakhee Vaidya has written about Vincristine.
Connection Strength
0.116
-
McPhail ED, Maurer MJ, Macon WR, Feldman AL, Kurtin PJ, Ketterling RP, Vaidya R, Cerhan JR, Ansell SM, Porrata LF, Nowakowski GS, Witzig TE, Habermann TM. Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica. 2018 11; 103(11):1899-1907.
Score: 0.041
-
Lamar ZS, Dothard A, Kennedy L, Isom S, Robinson M, Vaidya R, Hurd D, McClain D, Lesser G. Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Leuk Lymphoma. 2018 08; 59(8):1871-1877.
Score: 0.040
-
Lamar ZS, Fino N, Palmer J, Gruber L, Morris BB, Raetskaya-Solntseva O, Kennedy L, Vaidya R, Hurd D, Zamkoff K. Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With or Without Rituximab as First-Line Therapy for Aggressive Non-Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2016 Feb; 16(2):76-81.
Score: 0.035